bedrocan


# Bedromed spray

## Sublingual spray

Bedromed spray is a pharmaceutical grade cannabinoid formulation derived from Bedrocan's standardised *Cannabis sativa* L. chemovars. Formulated as a nano-emulsion, metered dose spray. It is designed to enhance sublingual absorption, improve bioavailability, and reduce pharmacokinetic variability. Bedromed spray provides prescribers with a precise and reproducible cannabinoid delivery system.

## Product information

MADE in the EU

- Optimised mucosal absorption through an **advanced emulsion**
- Derived from Bedrocan's standardised chemovars to ensure **consistent active ingredient composition**
- Engineered for **rapid onset** and **improved bioavailability** via a water-soluble formulation
- Guaranteed pharmaceutical-grade quality through **EU-GMP certified manufacturing**

| Active Substance | Formulation | Content / spray (140 µL) | Starting Material* | Carrier Oil | Shelf Life | Packaging Size |
|---|---|---|---|---|---|---|
| THC | **20 mg/mL** | 2.8 mg | Bedrocan® | LCT oil in water emulsion | 12 months | 30 mL |
| THC<br>CBD | **10 mg/mL**<br>**10 mg/mL** | 1.4 mg<br>1.4 mg | Bedrocan®<br>& Bedrolina® | LCT oil in water emulsion | 12 months | 30 mL |
| CBD | **20 mg/mL** | 2.8mg | Bedrolina® | LCT oil in water emulsion | 12 months | 30 mL |

THC only  Balanced  CBD only

*) **Bedrocan®**, *Cannabis sativa* L. 'Afina' | **Bedrolina®**, *Cannabis sativa* L. 'Janna'




**Medicine status**
Bedromed spray is supplied on prescription only, in accordance with the applicable national laws. Formulations containing THC are subject to controlled substance requirements under the relevant national legislation.

## About Bedrocan

Bedrocan is recognised as a pioneer in the production of pharmaceutical-grade medicinal cannabis. Since 2003, Bedrocan has supplied cannabis flower products manufactured to pharmaceutical standards, ensuring quality, safety, and reproducibility for inhalation therapies. To address evolving clinical needs, Bedrocan has expanded its portfolio to include EU-GMP-certified sublingual dosage forms such as Bedromed spray.

## Clinical use

**Intended use (emerging clinical evidence):** Bedromed spray is supplied under special access provisions as an unapproved oromucosal formulation. Current research on the pharmacological class of THC- and CBD-containing medicine has explored potential effects on pain perception and spasticity across several clinical conditions. Further clinical trials are required to determine the safety and efficacy of Bedromed spray. **Warnings and precautions:** Absolute and relative contraindications apply. Potential for medicine interactions must be considered.

## Dosing & titration

More info?
See **Treatment Planning**

Sublingual nano-emulsion spray, administered by a metered-dose pump delivering 140 microlitres (µL) per actuation.

**Individualised dose titration**

Principle: Start low, go slow.

**Starting dose and titration schedule (two-week period, days 1–14)**

One (1) spray, depending on formulation, delivers up to 2.8 mg THC and 2.8 mg CBD.

| Active Substance | Formulation | Dose Timing | | Maximum daily dose |
|---|---|---|---|---|
| | | Starting dose | Morning dose | |
| THC only | **20 mg/mL** | **1 spray, evening** | **Before 12 noon, if applicable** | **14 sprays (= 39.2 mg THC)** |
| Balanced | **THC 10 mg/mL CBD 10 mg/mL** | **1 spray, evening** | **Before 12 noon, if applicable** | **15 sprays (= 21 mg THC + 21 mg CBD)** |
| CBD only | **20 mg/mL** | **1 spray, evening** | **Before 12 noon, if applicable** | **15 sprays (= 42.0 mg CBD)** |

**Note:** Patient-specific dosing must be individualised.

## Ordering

### Ordering process for pharmacies

You can find ordering details at **www.bedrocan.com/order**.

The Certificate of Analysis (latest batch) is available from your distributor or pharmacy.



**Contact Bedrocan**
info@bedrocan.com
bedrocan.com